GPC Biotech’s mission is to discover, develop and commercialize new anticancer drugs. more
To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
GPC Biotech AG reported that its planned merger, under which the Company will combine its business with Agennix Incorporated remains on track to close before the end of 2009. The Company resulting from the merger will be called Agennix AG. The Company also reported a change to the future Managemen more
GPC Biotech AG announced that the shareholders' meeting approved the adoption of the merger agreement between the Company and diagennix GmbH (to be renamed Agennix AG and converted into a stock corporation). Pursuant to the merger agreement, GPC Biotech, as transferring entity, is to be merged into more
GPC Biotech AG and Agennix, Incorporated announced that the two oncology-focused biotechnology companies have signed a Business Combination Agreement under which they propose to merge their businesses. In the transaction, GPC Biotech is to be merged onto a new German company, which will hold all o more
What will this decade hold for leading anti-cancer drugs and that therapeutic market? Our new report shows you anti-cancer drug revenue forecasts for 2011 to 2021. We provide research, data and opinions to benefit your work now. What revenues will cancer treatment markets generate from 2011 to 2021 more
Agennix AG is a biopharmaceutical company resulting from the combination of GPC Biotech AG and Agennix. The company is engaged in development of novel therapies in Germany and the US. It research and development program of novel therapies is focused in areas of major unmet medical need to improve th more
Overview Business Strategy Management Team Board Of Directors Scientific Advisory Board Clinical Advisory Board From Heparin to Glycodrugs Endotis Pharma Drug Discovery Engine Targeted Diseases R&D Programs Board Of Directors Management Board Charles Woler, MD Chairman of the Board and Chief Executi more
Home About Suppremol Technology & Products News & Events Careers Down- loads Latest News Apr 19, 2010 SuppreMol Receives U.S. Orphan Drug Designation for SM101 Apr 12, 2010 SuppreMol initiates Phase Ib/IIa clinical trial with its lead candidate SM101 Feb 08, 2010 SuppreMol appoints Dr. Robert Phelps more
suppliers Wellington Laboratories more A world-leading producer and supplier of reference standards of potentially toxic, halogenated aromatic compounds that are of environmental concern. Since its inception in the late 1970’s, Wellington has become internationally respected as a reliable more
This is where you can add this topic to your personal favourites